GLCCI1

Across TCGA pan-cancer cohorts, GLCCI1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GLCCI1 data layer compared with 21 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher GLCCI1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated GLCCI1 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC, LUAD, and UCEC are the cancer types where GLCCI1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	III,IV	0.869	0.245	.006	19	view →
LUAD	DFS	Median	III,IV	0.308	0.694	.005	14	view →
UCEC	DFS	Median	All	0.922	1.000	.014	6	view →
CCRCC	DFS	Median	All	0.882	1.000	.017	4	view →
HNSC	OS	Median	All	0.945	1.000	.037	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GLCCI1–PDAC (OS)

Open the PDAC breakdown →